[1]朱志英,黄金智,李玉婷,等.单细胞测序技术在妇科恶性肿瘤中的应用[J].医学信息,2024,37(02):172-176.[doi:10.3969/j.issn.1006-1959.2024.02.037]
 ZHU Zhi-ying,HUANG Jin-zhi,LI Yu-ting,et al.Application of Single Cell Sequencing in Gynecological Malignant Tumor[J].Journal of Medical Information,2024,37(02):172-176.[doi:10.3969/j.issn.1006-1959.2024.02.037]
点击复制

单细胞测序技术在妇科恶性肿瘤中的应用()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年02期
页码:
172-176
栏目:
综述
出版日期:
2024-01-15

文章信息/Info

Title:
Application of Single Cell Sequencing in Gynecological Malignant Tumor
文章编号:
1006-1959(2024)02-0172-05
作者:
朱志英黄金智李玉婷
(1.广东医科大学第一临床医学院,广东 湛江 524000;2.深圳市龙华区中心医院妇产科,广东 深圳 518110;3.佛山市顺德区妇幼保健院妇科,广东 佛山 528300;4.广东医科大学附属医院妇产科,广东 湛江 524000)
Author(s):
ZHU Zhi-yingHUANG Jin-zhiLI Yu-tinget al.
(1.The First Clinical Medical College of Guangdong Medical University,Zhanjiang 524000,Guangdong,China;2.Department of Obstetrics and Gynecology,Shenzhen Longhua District Central Hospital,Shenzhen 518110,Guangdong,China;3.Department of Gynecology,Maternity&Child Healthcare Hospital of Shunde,Foshan 528300,Guangdong,China;4.Department of Obstetrics and Gynecology,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,Guangdong,China)
关键词:
单细胞测序技术妇科恶性肿瘤肿瘤微环境肿瘤异质性
Keywords:
Single cell sequencing technologyGynecological malignant tumorTumor microenvironmentHeterogeneity of tumor
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2024.02.037
文献标志码:
A
摘要:
妇科恶性肿瘤是因妇科恶性肿瘤细胞异质性程度高和复杂的微环境导致形成,为全球女性主要的死亡原因,严重威胁着全球女性的健康。单细胞RNA测序(scRNA-seq)技术指在单个细胞水平上,对基因组或转录组进行扩增并测序的一项变革性新技术,其最显著优势是精准度更高,能捕捉到稀有的基因和亚群,这是传统测序方法达不到的。因此,利用该技术有助于深入了解妇科恶性肿瘤的发生和发展机制、发现新的标记物和潜在治疗靶点等,有望为妇科恶性肿瘤患者的精准治疗提供理论基础。本文主要介绍单细胞测序技术在宫颈癌、子宫内膜癌和卵巢癌中的应用。
Abstract:
Gynecological malignant tumor is formed due to the high degree of heterogeneity of gynecological malignant tumor cells and the complex microenvironment, which is the main cause of death for women worldwide and seriously threatens the health of women worldwide. Single cell RNA sequencing (scRNA-seq) is a revolutionary new technology that amplifies and sequenced the genome or transcriptome at the level of a single cell. The most significant advantage is that it is more accurate and can capture rare genes and subsets, which are not accessible by traditional sequencing methods. Therefore, the use of this technology is helpful to deeply understand the occurrence and development mechanism of gynecological malignant tumors, discover new markers and potential therapeutic targets, and provide a theoretical basis for the precision treatment of patients with gynecological malignant tumors. This article mainly introduces the application of single-cell sequencing technology in cervical cancer, endometrial carcinoma and ovarian cancer.

参考文献/References:

[1]Fan C,Tu C,Qi P,et al.GPC6 Promotes Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma[J].J Cancer,2019,10(17):3926-3932.[2]Sun G,Li Z,Rong D,et al.Single-cell RNA sequencing in cancer: Applications, advances, and emerging challenges[J].Mol Ther Oncolytics,2021,21:183-206.[3]Chong ZX,Ho WY,Yeap SK,et al.Single-cell RNA sequencing in human lung cancer: Applications, challenges, and pathway towards personalized therapy[J].J Chin Med Assoc,2021,84(6):563-576.[4]Kan T,Zhang S,Zhou S,et al.Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence[J].Oncogene,2022,41(6):895-906.[5]Ysebaert L,Quillet-Mary A,Tosolini M,et al.Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics[J].Front Immunol,2021,12:597651.[6]McGranahan N,Swanton C.Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future[J].Cell,2017,168(4):613-628.[7]Sanger F,Nicklen S,Coulson AR.DNA sequencing with chain-terminating inhibitors[J].Proc Natl Acad Sci U S A.,1977,74(12):5463-5467.[8]Tang F,Barbacioru C,Wang Y,et al.mRNA-Seq whole-transcriptome analysis of a single cell[J].Nat Methods,2009,6(5):377-382.[9]Nagai H,Kim YH.Cancer prevention from the perspective of global cancer burden patterns[J].J Thorac Dis,2017,9(3):448-451.[10]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.[11]Zhang Y,Rumgay H,Li M,et al.Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling[J].JMIR Public Health Surveill,2023,9:e49968.[12]宋祎凡,刘晓雪,尹遵栋,等.2018-2020年中国9-45岁女性人乳头瘤病毒疫苗估算接种率[J].中国疫苗和免疫,2021,27(5):570-575.[13]Naik S,Larsen SB,Cowley CJ,et al.Two to Tango: Dialog between Immunity and Stem Cells in Health and Disease[J].Cell,2018,175(4):908-920.[14]Doorbar J,Griffin H.Refining our understanding of cervical neoplasia and its cellular origins[J].Papillomavirus Res,2019,7:176-179.[15]Chumduri C,Gurumurthy RK,Berger H,et al.Opposing Wnt signals regulate cervical squamocolumnar homeostasis and emergence of metaplasia[J].Nat Cell Biol,2021,23(2):184-197.[16]Prasetyanti PR,Medema JP.Intra-tumor heterogeneity from a cancer stem cell perspective[J].Mol Cancer,2017,16(1):41.[17]Li C,Guo L,Li S,et al.Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and transcriptional activities of ECs in CC[J].Mol Ther Nucleic Acids,2021,24:682-694.[18]Casey SC,Amedei A,Aquilano K,et al.Cancer prevention and therapy through the modulation of the tumor microenvironment[J].Semin Cancer Biol,2015,35 Suppl(Suppl):S199-S223.[19]Beuselinck B,Lambrechts D,Van Brussel T,et al.Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib[J].Acta Oncol,2014,53(10):1413-1422.[20]Wijaya J,Fukuda Y,Schuetz JD.Obstacles to Brain Tumor Therapy: Key ABC Transporters[J].Int J Mol Sci,2017,18(12):2544.[21]Li C,Hua K.Dissecting the Single-Cell Transcriptome Network of Immune Environment Underlying Cervical Premalignant Lesion, Cervical Cancer and Metastatic Lymph Nodes[J].Front Immunol,2022,13:897366.[22]周蓉,鹿群,刘国莉,等.早期子宫内膜癌保留生育功能治疗专家共识[J].中国妇产科临床杂志,2019,20(4):369-373.[23]Corzo C,Barrientos Santillan N,Westin SN,et al.Updates on Conservative Management of Endometrial Cancer[J].J Minim Invasive Gynecol,2018,25(2):308-313.[24]Siegel RL,Miller KD,Fuchs HE,et al.Cancer statistics, 2022[J].CA Cancer J Clin,2022,72(1):7-33.[25]Colombo N,Creutzberg C,Amant F,et al.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up[J].Ann Oncol,2016,27(1):16-41.[26]Hashimoto S,Tabuchi Y,Yurino H,et al.Comprehensive single-cell transcriptome analysis reveals heterogeneity in endometrioid adenocarcinoma tissues[J].Sci Rep,2017,7(1):14225.[27]Zhu Y,Lin X,Zang Y,et al.Identification of ZEB2 as an Immune-Associated Gene in Endometrial Carcinoma and Associated with Macrophage Infiltration by Bioinformatic Analysis[J].J Healthc Eng,2021,2021:4372373.[28]Guo YE,Li Y,Cai B,et al.Phenotyping of immune and endometrial epithelial cells in endometrial carcinomas revealed by single-cell RNA sequencing[J].Aging (Albany NY),2021,13(5):6565-6591.[29]Fu DJ,De Micheli AJ,Bidarimath M,et al.Cells expressing PAX8 are the main source of homeostatic regeneration of adult mouse endometrial epithelium and give rise to serous endometrial carcinoma[J].Dis Model Mech,2020,13(10):dmm047035.[30]Cochrane DR,Campbell KR,Greening K,et al.Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours[J].J Pathol,2020,252(2):201-214.[31]Stuart GC,Kitchener H,Bacon M,et al.2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference[J].Int J Gynecol Cancer,2011,21(4):750-755.[32]Winterhoff BJ,Maile M,Mitra AK,et al.Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells [published correction appears in Gynecol Oncol[J].Gynecol Oncol,2017,144(3):598-606.[33]Hao Q,Li J,Zhang Q,et al.Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma[J].Clin Transl Med,2021,11(8):e500.[34]Geistlinger L,Oh S,Ramos M,et al.Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma[J].Cancer Res,2020,80(20):4335-4345.[35]Izar B,Tirosh I,Stover EH,et al.A single-cell landscape of high-grade serous ovarian cancer[J].Nat Med,2020,26(8):1271-1279.[36]Olbrecht S,Busschaert P,Qian J,et al.High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification[J].Genome Med,2021,13(1):111.[37]Olalekan S,Xie B,Back R,et al.Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics[J].Cell Rep,2021,35(8):109165.[38]Wan C,Keany MP,Dong H,et al.Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer[J].Cancer Res,2021,81(1):158-173.[39]Nath A,Cosgrove PA,Mirsafian H,et al.Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer[J].Nat Commun,2021,12(1):3039.[40]Hu Z,Artibani M,Alsaadi A,et al.The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells[J].Cancer Cell,2020,7(2):226-242.e7.[41]Liang L,Yu J,Li J,et al.Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model[J].Front Oncol,2021,11:711020.

相似文献/References:

[1]张晓黎,张 颖,陈国通,等.环状RNA在妇科恶性肿瘤中的研究进展[J].医学信息,2020,33(03):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]
 ZHANG Xiao-li,ZHANG Ying,CHEN Guo-tong,et al.Study of Circular RNA in Gynecological Malignancies[J].Journal of Medical Information,2020,33(02):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]

更新日期/Last Update: 1900-01-01